AZ’s Susan Galbraith On What’s Next In The Cancer Pipeline

One of the architects of AstraZeneca’s burgeoning cancer portfolio, oncology R&D head Susan Galbraith is making sure the firm does not rest on its laurels. She talked to In Vivo about what’s coming next from the UK major’s cancer pipeline.